Biogen Inc. (0R1B.L) LSE
190.74
-4.26(-2.18%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Biogen Inc.
Address
225 Binney St
Cambridge, MA
United States of America (the)
Phone
17814642000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7605
First IPO Date
September 17, 1991
Key Executives
| Name | Title | Pay | Year Born |
| Christopher A. Viehbacher | President, Chief Executive Officer & Director | 5.28M | 1961 |
| Rachid Izzar | Executive Vice President and Head of Global Product Strategy & Commercialization | 1.27M | 1975 |
| Ginger Gregory | Executive Vice President & Chief Human Resources Officer | 1.59M | 1968 |
| Robin C. Kramer | Executive Vice President & Chief Financial Officer | 1.63M | 1966 |
| Priya Singhal | Executive Vice President & Head of Development | 2.01M | 1968 |
| Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology | 2.01M | 1973 |
| Susan H. Alexander | Executive Vice President & Chief Legal Officer | 2.25M | 1957 |
| Anabella Villalobos | Head of Biotherapeutics & Medicinal Sciences | 0 | 1960 |
| Adam Keeney | Executive Vice President & Head of Corporate Development | 0 | 1977 |
| Tim Power | Head of Investor Relations | 0 | N/A |
| Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | 0 | N/A |
| Fraser Hall | President & Head of Intercontinental Region | 0 | N/A |
| Alisha A. Alaimo | President & Head of North America | 0 | N/A |
| Guy Hadari | Chief Information Officer | 0 | N/A |
| Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | 0 | 1974 |
Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
